US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
| ZONEGRAN | 100MG; 25MG | capsule · oral | ADVANZ PHARMA | Prescription | 27 Mar 2000 |
| ZONISAMIDE | 100MG; 50MG; 25MG | capsule · oral | GRANULES | Prescription | 22 Dec 2005 |
| ZONISAMIDE | 100MG; 25MG; 50MG | capsule · oral | AUROBINDO PHARMA LTD | Prescription | 22 Dec 2005 |
| ZONISAMIDE | 25MG; 50MG; 100MG | capsule · oral | GLENMARK PHARMS | Prescription | 30 Jan 2006 |
| ZONISAMIDE | 25MG; 50MG; 100MG | capsule · oral | INVAGEN PHARMS | Prescription | 31 May 2006 |
| ZONISAMIDE | 25MG; 50MG; 100MG | capsule · oral | BIONPHARMA | Prescription | 16 Aug 2006 |
| ZONISAMIDE | 25MG; 50MG; 100MG | capsule · oral | ZYDUS LIFESCIENCES | Prescription | 16 Oct 2006 |
| ZONISAMIDE | 25MG; 50MG; 100MG | capsule · oral | UNICHEM | Prescription | 26 Jan 2021 |
| ZONISADE | 100MG/5ML | suspension · oral | AZURITY | Prescription | 15 Jul 2022 |
| ZONEGRAN | 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | ADVANZ PHARMA | Discontinued | 27 Mar 2000 |
| ZONISAMIDE | 25MG; 50MG; 100MG | capsule · oral | SUN PHARM INDUSTRIES | Discontinued | 22 Dec 2005 |
| ZONISAMIDE | 25MG; 50MG; 100MG | capsule · oral | RISING | Discontinued | 22 Dec 2005 |
| ZONISAMIDE | 25MG; 50MG; 100MG | capsule · oral | ANI PHARMS | Discontinued | 22 Dec 2005 |
| ZONISAMIDE | 100MG; 50MG; 25MG | capsule · oral | ANI PHARMS | Discontinued | 22 Dec 2005 |
| ZONISAMIDE | 25MG; 50MG; 100MG | capsule · oral | APOTEX | Discontinued | 22 Dec 2005 |
| ZONISAMIDE | 25MG; 50MG; 100MG | capsule · oral | UPSHER SMITH LABS | Discontinued | 22 Dec 2005 |
| ZONISAMIDE | 25MG; 50MG; 100MG | capsule · oral | PHARMOBEDIENT | Discontinued | 22 Dec 2005 |
| ZONISAMIDE | 25MG; 50MG; 100MG | capsule · oral | ROXANE | Discontinued | 22 Dec 2005 |
| ZONISAMIDE | 25MG; 50MG; 100MG | capsule · oral | SUN PHARM INDS (IN) | Discontinued | 17 Mar 2006 |
| ZONISAMIDE | 25MG; 50MG; 100MG | capsule · oral | CHARTWELL RX | Discontinued | 20 Apr 2006 |
| ZONISAMIDE | 25MG; 50MG; 100MG | capsule · oral | EPIC PHARMA LLC | Discontinued | 21 Feb 2007 |
| ZONISAMIDE | 25MG; 50MG; 100MG | capsule · oral | MACLEODS PHARMS | Discontinued | 12 May 2025 |
EMA European Union — centrally authorised medicines
Zonegran Amdipharm Limited · Authorised · authorised 10 Mar 2005 · ATC N03AX15
Therapeutic indication (EMA)
Zonegran is indicated as: monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged six years and above.
Therapeutic indication (EMA)
Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
| US NADAC | ZONISADE 100 MG/5 ML ORAL SUSP | $2.75055 | per ML | 23 Sep 2026 |
| US NADAC | ZONISAMIDE 100 MG CAPSULE | $0.10618 | per EA | 23 Sep 2026 |
| US NADAC | ZONISAMIDE 25 MG CAPSULE | $0.06546 | per EA | 23 Sep 2026 |
| US NADAC | ZONISAMIDE 50 MG CAPSULE | $0.0955 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Zonisamide 100mg capsules | £3.52 | 56 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Zonisamide 100mg/5ml oral suspension | £181.90 | 250 ml | 1 Oct 2026 |
| NHS Drug Tariff | Zonisamide 25mg capsules | £2.32 | 14 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Zonisamide 50mg capsules | £3.49 | 56 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.